Healthcare growth equity fund research profile
Quadria Capital Fund III is a healthcare-focused Asia private-equity vehicle with public India deployment evidence. The manager disclosed the fund's 2025 close and deployment, while company and manager materials identify healthcare platforms including Aragen Life Sciences, NephroPlus, Maxivision Eye Hospitals, Akums and Encube.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Quadria Capital Fund III uses a healthcare growth equity approach across Hospitals, pharmaceuticals, diagnostics.
Current evidence
Quadria Capital announced the oversubscribed final close of Fund III at US$1.07 billion in May 2025 and reported early deployment into Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 annual review also records the Akums IPO partial exit and continued activity across Fund III healthcare platforms.
Strategy
Healthcare growth equity
Sector focus
Hospitals, pharmaceuticals, diagnostics
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Quadria Capital announced the oversubscribed final close of Fund III at US$1.07 billion in May 2025 and reported early deployment into Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 annual review also records the Akums IPO partial exit and continued activity across Fund III healthcare platforms.
Investor questions
Quadria Capital Fund III is covered in Rupeia's private equity research universe. The current public record describes the strategy as Healthcare growth equity, with a sector focus of Hospitals, pharmaceuticals, diagnostics. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Quadria Capital Fund III in the reviewed public sources: Aragen Life Sciences, NephroPlus, Maxivision Eye Hospitals, Akums Drugs and Pharmaceuticals, Encube Ethicals. It does not represent a complete current portfolio unless the manager has published one.
Quadria's 2025–26 annual review and fund-close announcement identify current Fund III deployment and healthcare portfolio companies. Fund-level realised returns and net performance are not publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: US$1.07 billion final close, announced in May 2025.. Public terms or access information: Healthcare growth and buyout investments across Asia, with India exposure; vehicle fees, carry, ownership and reserve terms are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Abrar Mir (Co-Founder & Managing Partner); Amit Varma (Co-Founder & Managing Partner). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: India-versus-Southeast Asia allocation and fund-level net returns remain not publicly disclosed..
2025-05-27: Quadria Capital announced the oversubscribed final close of Fund III at US$1.07 billion in May 2025 and reported early deployment into Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 annual review also records the Akums IPO partial exit and continued activity across Fund III healthcare platforms.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.